Eli Lilly and Co (BUE:LLY) Research & Development: ARS19,092,868 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:LLY Eli Lilly and Co BUE:LLY
97 GF Score
Price ARS33,300.00
GF Value ARS39,010.00
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Eli Lilly and Co Research & Development?

Eli Lilly and Co BUE:LLY +0.18% 97 Research & Development is ARS19,092,868 Mil as of Mar. 2026. GuruFocus rates BUE:LLY with a GF Score™ of 97/100 and a GF Value™ of ARS39,010.00 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Eli Lilly and Co's Research & Development for the three months ended in Mar. 2026 was ARS4,907,840 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ARS19,092,868 Mil.

Eli Lilly and Co  (BUE:LLY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Eli Lilly and Co Research & Development Related Terms

Eli Lilly and Co Research & Development Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Research & Development Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 699,931.38 1,205,537.59 3,361,993.00 11,100,910.11 19,358,508.64

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,914,544.99 3,960,728.70 4,706,463.58 5,517,835.39 4,907,840.27
BUE:LLY
97GF Score
Eli Lilly and Co BUE:LLY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS19,092,868 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ARS19,092,868 Mil mean?
Eli Lilly and Co (BUE:LLY) has a Research & Development of ARS19,092,868 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Eli Lilly and Co and its competitors.
Is Eli Lilly and Co's Research & Development too high?
Eli Lilly and Co's current Research & Development is ARS19,092,868 Mil. Overall, Eli Lilly and Co has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Research & Development compare to JNJ and ABBV?
Eli Lilly and Co's Research & Development of ARS19,092,868 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Eli Lilly and Co and its competitors. Eli Lilly and Co's current Research & Development is ARS19,092,868 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (BUE:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS39,010.00, compared to a current price of ARS33,300.00 — trading 14.6% below its estimated fair value. The current Research & Development is ARS19,092,868 Mil. Eli Lilly and Co's overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Eli Lilly and Co (BUE:LLY), the current Research & Development is ARS19,092,868 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (BUE:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of ARS33,300.00 is trading 14.6% below its estimated GF Value™ of ARS39,010.00. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BUE:LLY:

  • Research & Development: ARS19,092,868 Mil
  • GF Value™: ARS39,010.00 vs. price of ARS33,300.00 (14.6% below fair value)
  • GF Score™: 97/100 with 5 warning signs

No single metric tells the full story. See the BUE:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for BUE:LLY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS33,300.00
Price
ARS39,010.00
GF Value